Valuation: SENSORION

Market Cap 149M 172M 139M 127M 240M 16.37B 243M 1.63B 640M 8.2B 646M 632M 27.12B P/E 2026 *
-38.5x
P/E 2027 * -6.42x
Enterprise Value 16.75M 19.37M 15.65M 14.35M 27M 1.84B 27.42M 184M 72.05M 924M 72.73M 71.14M 3.05B EV / Sales 2026 *
0.77x
EV / Sales 2027 * 23.3x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 2026-05-31
Director of Finance/CFO - 2024-06-25
Chief Tech/Sci/R&D Officer - 2023-12-10
Director TitleAgeSince
Director/Board Member - 2015-03-08
Director/Board Member 43 -
Chairman 61 2023-03-29
Change 5-day change 1-year change 3-year change Capi.($)
+0.99%+0.35%+4.91%+16.06% 48.7B
+3.71%+6.75%+459.45%+557.32% 42.05B
+2.70%+0.38%+34.49%+10.04% 38.26B
+5.60%+8.13%+16.67%+72.18% 37.5B
+2.21%+4.89%+17.24%+51.64% 31.44B
+2.23%+1.73% - - 16.47B
+0.97%+2.14%+37.25%+128.28% 16.33B
-0.11%+1.75%+8.05%+18.47% 13.98B
+0.75%+14.01%+77.94%+29.28% 12.68B
Average +2.12%+3.06%+82.00%+110.41% 28.6B
Weighted average by Cap. +2.52%+2.31%+98.60%+131.40%

Financials

2026 *2027 *
Net sales 21.86M 25.27M 20.41M 18.73M 35.22M 2.4B 35.78M 239M 94M 1.21B 94.89M 92.81M 3.99B 6.4M 7.39M 5.97M 5.48M 10.3M 704M 10.47M 70.07M 27.5M 353M 27.76M 27.15M 1.17B
Net income -237K -274K -221K -203K -381K -26.04M -387K -2.59M -1.02M -13.05M -1.03M -1M -43.15M -36.12M -41.76M -33.73M -30.94M -58.2M -3.97B -59.12M -396M -155M -1.99B -157M -153M -6.59B
Net Debt -132M -153M -123M -113M -213M -14.52B -216M -1.45B -568M -7.28B -573M -561M -24.07B -
Logo SENSORION
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-